AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Agenus Receives Buy Rating: Clinical Trials and Partnerships Fuel Growth Potential
ByAinvest
Thursday, Aug 28, 2025 7:28 am ET1min read
Agenus receives a Buy rating from Emily Bodnar due to promising clinical trials and strategic partnerships. The company is advancing its botensilimab and balstilimab development, with a Phase 3 trial set to begin in Q4 2025, and has collaborated with the Canadian Cancer Trials Group to facilitate efficient patient enrollment. Bodnar's confidence in the company's growth potential justifies the Buy rating.
Agenus Inc. (Nasdaq: AGEN), a clinical-stage biotechnology company specializing in cancer and infection therapies, has received a Buy rating from financial analyst Emily Bodnar. The rating reflects the company's promising clinical trial results and strategic partnerships, particularly in the development of botensilimab and balstilimab.Agenus is advancing its botensilimab and balstilimab development, with a Phase 3 trial set to begin in Q4 2025. Botensilimab, a multifunctional, human Fc-enhanced CTLA-4 blocking antibody, has demonstrated clinical responses across nine metastatic, late-line cancers. Balstilimab, a novel, fully human PD-1 blocking antibody, has shown clinical activity and a favorable tolerability profile in several tumor types [1].
The company has also collaborated with the Canadian Cancer Trials Group (CCTG) to facilitate efficient patient enrollment in its clinical trials. This partnership aims to streamline the enrollment process and accelerate the development of innovative therapies [2].
Bodnar's confidence in Agenus' growth potential is underpinned by the company's comprehensive pipeline of immunological agents and robust end-to-end development capabilities. The analyst believes that Agenus' strategic partnerships and clinical advancements position the company favorably for future success.
References:
[1] https://ca.finance.yahoo.com/quote/AGEN/
[2] https://www.marketscreener.com/news/agenus-aug-27-stakeholder-webcasta-transformative-io-updates-bot-bal-data-battman-preview-zydus-ce7c50d9da8bf12d
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet